Base de datos : MEDLINE
Búsqueda : sida or vih [Palabras]
Referencias encontradas : 276386 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 27639 va a la página                         

  1 / 276386 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:24906850
[Au] Autor:Shah SK; Persaud D; Wendler DS; Taylor HA; Gay H; Kruger M; Grady C
[Ad] Dirección:Clinical Center Department of Bioethics, National Institutes of Health, Bethesda, MD, USA. Electronic address: shahse@mail.nih.gov....
[Ti] Título:Research into a functional cure for HIV in neonates: the need for ethical foresight.
[So] Fuente:Lancet Infect Dis;14(9):893-8, 2014 Sep.
[Is] ISSN:1474-4457
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:In 2013, researchers announced that a newborn child from Mississippi, USA might have been functionally cured of HIV by being given combination antiretroviral therapy within hours of birth. Public and media attention has since been captured by the possibility of finding a cure for HIV transmitted from mother to child. Research into the strategy used for the Mississippi patient is crucially important to establish whether it can be replicated and shown to work in diverse populations. At the same time, any ethical issues likely to arise in such studies should be addressed and not ignored in the pursuit of a functional cure. In this Personal View we identify ethical issues that could arise in research towards achievment of a functional cure for HIV in neonates, including difficult trade-offs associated with choosing the study population and questions about the broader social implications of the research, and propose ways to resolve them.
[Mh] Términos MeSH primario: Investigación Biomédica
Infecciones por VIH/quimioterapia
Transmisión Vertical de Enfermedad Infecciosa
[Mh] Términos MeSH secundario: Investigación Biomédica/ética
Humanos
Recién Nacido
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Em] Mes de ingreso:1410
[Cu] Fecha actualización por clase:141105
[Lr] Fecha última revisión:141105
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:140828
[St] Status:MEDLINE


  2 / 276386 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:25011556
[Au] Autor:Wagner TA; McLaughlin S; Garg K; Cheung CY; Larsen BB; Styrchak S; Huang HC; Edlefsen PT; Mullins JI; Frenkel LM
[Ad] Dirección:Seattle Children's Research Institute, 1900 9th Avenue, Seattle, WA 98101, USA. University of Washington, Seattle, WA, USA....
[Ti] Título:HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection.
[So] Fuente:Science;345(6196):570-3, 2014 Aug 1.
[Is] ISSN:1095-9203
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Antiretroviral treatment (ART) of HIV infection suppresses viral replication. Yet if ART is stopped, virus reemerges because of the persistence of infected cells. We evaluated the contribution of infected-cell proliferation and sites of proviral integration to HIV persistence. A total of 534 HIV integration sites (IS) and 63 adjacent HIV env sequences were derived from three study participants over 11.3 to 12.7 years of ART. Each participant had identical viral sequences integrated at the same position in multiple cells, demonstrating infected-cell proliferation. Integrations were overrepresented in genes associated with cancer and favored in 12 genes across multiple participants. Over time on ART, a greater proportion of persisting proviruses were in proliferating cells. HIV integration into specific genes may promote proliferation of HIV-infected cells, slowing viral decay during ART.
[Mh] Términos MeSH primario: Genes Relacionados con las Neoplasias
Infecciones por VIH/virología
VIH-1/fisiología
Integración Viral
Latencia del Virus
[Mh] Términos MeSH secundario: Fármacos Anti-VIH/uso terapéutico
Secuencia de Bases
Factores de Transcripción con Cremalleras de Leucina de Carácter Básico/genética
Proliferación de la Célula
Cromosomas Humanos Par 6/genética
Sitios Genéticos
Infecciones por VIH/quimioterapia
VIH-1/genética
Humanos
Células Jurkat
Datos de Secuencia Molecular
Filogenia
Replicación Viral
Productos del Gen env del Virus de la Inmunodeficiencia Humana/clasificación
Productos del Gen env del Virus de la Inmunodeficiencia Humana/genética
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Anti-HIV Agents); 0 (BACH2 protein, human); 0 (Basic-Leucine Zipper Transcription Factors); 0 (env Gene Products, Human Immunodeficiency Virus)
[Em] Mes de ingreso:1408
[Cu] Fecha actualización por clase:141105
[Lr] Fecha última revisión:141105
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:140801
[St] Status:MEDLINE
[do] DOI:10.1126/science.1256304


  3 / 276386 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:24643443
[Au] Autor:Zhu C; Geng Q; Chen L; Yang H; Jiang W
[Ad] Dirección:Department of Preventive Medicine, School of Public Health, Guangzhou Medical University, Guangzhou, 510182, People's Republic of China.
[Ti] Título:Impact of an educational programme on reproductive health among young migrant female workers in Shenzhen, China: an intervention study.
[So] Fuente:Int J Behav Med;21(4):710-8, 2014 Aug.
[Is] ISSN:1532-7558
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Reproductive health and sexually transmitted diseases (STD) account for a high proportion of health problems in the rural-to-urban young female migrant workers in China. Improving these conditions remains highly challenging. PURPOSE: To developed an educational programme to advance the reproductive health of the female workers. METHOD: An intervention study was conducted between July 2010 and April 2011 in Shenzhen. Two commune factories were selected to participate and provided a control cluster receiving routine local government health services and a second cluster receiving an educational intervention in addition to the routine services. The intervention included distribution and free access to educational study materials. The factory workers' knowledge, attitudes and behaviour in the area of reproductive health and STD were the main study outcomes. RESULTS: Compared with the control cluster, at the 6-month follow-up assessment, the intervention cluster had a significantly higher proportion of correct answers to queries about human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) (standardised coefficients of multiple linear regression (B) 0.047; P = 0.020) and awareness of places providing free contraceptives (odds ratio [OR] 2.011, 95% confidence interval [CI] 1.635-2.472; P < 0.001), and a significantly lower proportion accepting premarital sex (OR 0.492, 95% CI 0.416-0.582; P < 0.001), practising premarital sex (OR 0.539, 95% CI 0.478-0.608; P < 0.001) or suffering from gynaecological disorders (OR 0.801, 95% CI 0.697-0.921; P = 0.002). CONCLUSION: A community-based educational intervention targeting unmarried female migrant workers appears to be effective in substantially improving their knowledge of reproductive health and their attitudes and behaviour towards health, and in reducing prevalence of STD.
[Mh] Términos MeSH primario: Conocimientos, Actitudes y Práctica en Salud
Salud Reproductiva
Enfermedades de Transmisión Sexual/prevención & control
Migrantes/estadística & datos numéricos
[Mh] Términos MeSH secundario: Síndrome de Inmunodeficiencia Adquirida/prevención & control
Adolescente
Adulto
China/epidemiología
Estudios Transversales
Femenino
Infecciones por VIH/prevención & control
Humanos
Estudios de Intervención
Población Rural
Migrantes/psicología
Población Urbana
Adulto Joven
[Pt] Tipo de publicación:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Mes de ingreso:1411
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:140723
[St] Status:MEDLINE
[do] DOI:10.1007/s12529-014-9401-y


  4 / 276386 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:25014689
[Au] Autor:Gandhi M; Gandhi RT
[Ti] Título:Single-pill combination regimens for treatment of HIV-1 infection.
[So] Fuente:N Engl J Med;371(3):248-59, 2014 Jul 17.
[Is] ISSN:1533-4406
[Cp] País de publicación:United States
[La] Idioma:eng
[Mh] Términos MeSH primario: Antirretrovirales/administración & dosificación
Infecciones por VIH/quimioterapia
VIH-1/fisiología
[Mh] Términos MeSH secundario: Recuento de Linfocito CD4
Combinación de Medicamentos
Inhibidores de Integrasa VIH/administración & dosificación
Compuestos Heterocíclicos con 3 Anillos/administración & dosificación
Humanos
Masculino
Cumplimiento de la Medicación
Mediana Edad
[Pt] Tipo de publicación:JOURNAL ARTICLE; REVIEW
[Nm] Nombre de substancia:
0 (Anti-Retroviral Agents); 0 (Drug Combinations); 0 (HIV Integrase Inhibitors); 0 (Heterocyclic Compounds, 3-Ring); DKO1W9H7M1 (dolutegravir)
[Em] Mes de ingreso:1407
[Cu] Fecha actualización por clase:141106
[Lr] Fecha última revisión:141106
[Sb] Subgrupo de revista:AIM; IM
[Da] Fecha de ingreso para procesamiento:140712
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMct1215532


  5 / 276386 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:24602776
[Au] Autor:Ogunniyi AO; Thomas BA; Politano TJ; Varadarajan N; Landais E; Poignard P; Walker BD; Kwon DS; Love JC
[Ad] Dirección:Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States....
[Ti] Título:Profiling human antibody responses by integrated single-cell analysis.
[So] Fuente:Vaccine;32(24):2866-73, 2014 May 19.
[Is] ISSN:1873-2518
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:Comprehensive characterization of the antigen-specific B cells induced during infections or following vaccination would facilitate the discovery of novel antibodies and inform how interventions shape protective humoral responses. The analysis of human B cells and their antibodies has been performed using flow cytometry to evaluate memory B cells and expanded plasmablasts, while microtechnologies have also provided a useful tool to examine plasmablasts/plasma cells after vaccination. Here we present an integrated analytical platform, using arrays of subnanoliter wells (nanowells), for constructing detailed profiles for human B cells comprising the immunophenotypes of these cells, the distribution of isotypes of the secreted antibodies, the specificity and relative affinity for defined antigens, and for a subset of cells, the genes encoding the heavy and light chains. The approach combines on-chip image cytometry, microengraving, and single-cell RT-PCR. Using clinical samples from HIV-infected subjects, we demonstrate that the method can identify antigen-specific neutralizing antibodies, is compatible with both plasmablasts/plasma cells and activated memory B cells, and is well-suited for characterizing the limited numbers of B cells isolated from tissue biopsies (e.g., colon biopsies). The technology should facilitate detailed analyses of human humoral responses for evaluating vaccines and their ability to raise protective antibody responses across multiple anatomical compartments.
[Mh] Términos MeSH primario: Formación de Anticuerpos/inmunología
Linfocitos B/inmunología
Inmunofenotipificación/métodos
Análisis de la Célula Individual/métodos
[Mh] Términos MeSH secundario: Animales
Anticuerpos Neutralizantes/inmunología
Células CHO
Cricetulus
Citometría de Flujo
Células HEK293
Infecciones por VIH/inmunología
Humanos
Hibridomas
Isotipos de Inmunoglobulinas/inmunología
Memoria Inmunológica
Pruebas de Neutralización
Células Plasmáticas/inmunología
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Antibodies, Neutralizing); 0 (Immunoglobulin Isotypes)
[Em] Mes de ingreso:1411
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:140505
[St] Status:MEDLINE


  6 / 276386 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PubMed Central Texto completo
Texto completo
[PMID]:24561393
[Au] Autor:Martin MA; Hoffman JM; Freimuth RR; Klein TE; Dong BJ; Pirmohamed M; Hicks JK; Wilkinson MR; Haas DW; Kroetz DL; Clinical Pharmacogenetics Implementation Consortium
[Ad] Dirección:Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA....
[Ti] Título:Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.
[So] Fuente:Clin Pharmacol Ther;95(5):499-500, 2014 May.
[Is] ISSN:1532-6535
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing were originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplementary Material online and included additional resources for applying CPIC guidelines to the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).
[Mh] Términos MeSH primario: Fármacos Anti-VIH/administración & dosificación
Didesoxinucleósidos/administración & dosificación
Antígenos HLA-B/genética
[Mh] Términos MeSH secundario: Registros Electrónicos de Salud
Genotipo
Humanos
Farmacogenética
[Pt] Tipo de publicación:JOURNAL ARTICLE; PRACTICE GUIDELINE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nombre de substancia:
0 (Anti-HIV Agents); 0 (Dideoxynucleosides); 0 (HLA-B Antigens); WR2TIP26VS (abacavir)
[Em] Mes de ingreso:1406
[Cu] Fecha actualización por clase:141105
[Lr] Fecha última revisión:141105
[Sb] Subgrupo de revista:AIM; IM
[Da] Fecha de ingreso para procesamiento:140421
[St] Status:MEDLINE
[do] DOI:10.1038/clpt.2014.38


  7 / 276386 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:24165884
[Au] Autor:Kakuda TN; Van Solingen-Ristea RM; Onkelinx J; Stevens T; Aharchi F; De Smedt G; Peeters M; Leopold L; Hoetelmans RM
[Ad] Dirección:Janssen Research & Development, LLC, Titusville, NJ.
[Ti] Título:The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
[So] Fuente:J Clin Pharmacol;54(4):422-31, 2014 Apr.
[Is] ISSN:1552-4604
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:The effect of etravirine on cytochrome P450 (CYP) enzymes and P-glycoprotein were evaluated in two randomized, crossover trials in healthy subjects. A modified Cooperstown 5 + 1 cocktail was utilized to determine the effects of etravirine on single-dose pharmacokinetics of model CYP probes. The cocktail was administered alone, then, after a 14-day washout, etravirine 200 mg twice daily (bid) was given for 14 days with cocktail on days 1 and 14. In a separate study, digoxin (0.5 mg) was administered alone, then, after a 14-day washout, etravirine 200 mg bid was administered for 12 days with digoxin on day 8. In the cocktail study, the AUClast least squares mean (LSM) ratios (90% confidence intervals [CIs]) for cocktail + etravirine versus cocktail were 0.93 (0.88, 0.99; paraxanthine), 0.58 (0.44, 0.75; 7-OH-S-warfarin), 0.43 (0.20, 0.96; 5-OH-omeprazole), 0.85 (0.78, 0.94; dextrorphan), and 0.69 (0.64, 0.74; midazolam). Digoxin AUC0-8h was slightly increased with etravirine coadministration (LSM ratio 1.18 [0.90, 1.56]). These data suggest that etravirine is a weak CYP3A isozyme inducer and minimally inhibits CYP2C9, 2C19, and P-glycoprotein activity.
[Mh] Términos MeSH primario: Fármacos Anti-VIH/administración & dosificación
Sistema Enzimático del Citocromo P-450/metabolismo
Digoxina/administración & dosificación
P-Glicoproteína/metabolismo
Piridazinas/administración & dosificación
Inhibidores de Transcriptasa Inversa/administración & dosificación
[Mh] Términos MeSH secundario: Adolescente
Adulto
Cafeína/administración & dosificación
Cafeína/farmacocinética
Estudios Cruzados
Dextrometorfano/administración & dosificación
Dextrometorfano/farmacocinética
Digoxina/farmacocinética
Femenino
Voluntarios Sanos
Humanos
Masculino
Midazolam/administración & dosificación
Midazolam/farmacocinética
Mediana Edad
Omeprazol/administración & dosificación
Omeprazol/farmacocinética
Teofilina/administración & dosificación
Teofilina/farmacocinética
Warfarina/administración & dosificación
Warfarina/farmacocinética
Adulto Joven
[Pt] Tipo de publicación:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Anti-HIV Agents); 0 (P-Glycoprotein); 0 (Pyridazines); 0 (Reverse Transcriptase Inhibitors); 0C50HW4FO1 (etravirine); 3G6A5W338E (Caffeine); 5Q7ZVV76EI (Warfarin); 7355X3ROTS (Dextromethorphan); 73K4184T59 (Digoxin); 9035-51-2 (Cytochrome P-450 Enzyme System); C137DTR5RG (Theophylline); KG60484QX9 (Omeprazole); Q3565Y41V7 (1,7-dimethylxanthine); R60L0SM5BC (Midazolam)
[Em] Mes de ingreso:1411
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:140312
[St] Status:MEDLINE
[do] DOI:10.1002/jcph.214


  8 / 276386 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:24142299
[Au] Autor:Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S
[Ad] Dirección:Gilead Sciences, Inc., Foster City, CA, 94404, USA.
[Ti] Título:Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
[So] Fuente:J Clin Pharmacol;54(4):378-85, 2014 Apr.
[Is] ISSN:1552-4604
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:The effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (STR) was evaluated in healthy subjects. Subjects (N = 24) received rilpivirine/emtricitabine/tenofovir disoproxil fumarate (25/200/300 mg) under fasted or fed conditions (light [390 kcal, 12 g fat]; standard [540 kcal, 21 g fat]) followed by pharmacokinetic (PK) sampling. The 90% confidence interval (CI) of the geometric mean ratio for rilpivirine, emtricitabine, tenofovir exposure was estimated for fed versus fasted dosing and light versus standard meal, with equivalence boundaries of 80 - 125%. Safety was assessed throughout study. Twenty-three subjects completed the study; one discontinued due to protocol violation. Adverse events were mild to moderate. Emtricitabine PK was unaffected. Tenofovir AUCinf was 38% and 28% higher, respectively, with standard and light meal versus fasted. Rilpivirine AUCinf and Cmax were 16% and 26% higher with a standard, and 9% and 34% with a light meal, respectively, versus fasted. Compared to standard meal, the lower limit of rilpivirine AUClast and AUCinf when taken with the light meal were narrowly below the equivalence bounds (79.9 and 79.2, respectively), rilpivirine Cmax was narrowly above (129). Rilpivirine/emtricitabine/tenofovir disoproxil fumarate should be administered with food, which can be a standard or light meal.
[Mh] Términos MeSH primario: Adenina/análogos & derivados
Fármacos Anti-VIH/farmacocinética
Desoxicitidina/análogos & derivados
Interacciones Alimento-Droga
Infecciones por VIH/metabolismo
Nitrilos/farmacocinética
Organofosfonatos/farmacocinética
Pirimidinas/farmacocinética
[Mh] Términos MeSH secundario: Adenina/administración & dosificación
Adenina/efectos adversos
Adenina/farmacocinética
Adulto
Fármacos Anti-VIH/administración & dosificación
Fármacos Anti-VIH/efectos adversos
Estudios Cruzados
Desoxicitidina/administración & dosificación
Desoxicitidina/efectos adversos
Desoxicitidina/farmacocinética
Combinación de Medicamentos
Ayuno/metabolismo
Femenino
Infecciones por VIH/quimioterapia
Humanos
Masculino
Mediana Edad
Nitrilos/administración & dosificación
Nitrilos/efectos adversos
Organofosfonatos/administración & dosificación
Organofosfonatos/efectos adversos
Pirimidinas/administración & dosificación
Pirimidinas/efectos adversos
Comprimidos
Adulto Joven
[Pt] Tipo de publicación:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Anti-HIV Agents); 0 (Drug Combinations); 0 (Nitriles); 0 (Organophosphonates); 0 (Pyrimidines); 0 (Tablets); 0 (emtricitabine); 0 (tenofovir disoproxil); 0W860991D6 (Deoxycytidine); 500287-72-9 (Rilpivirine); JAC85A2161 (Adenine)
[Em] Mes de ingreso:1411
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:140312
[St] Status:MEDLINE
[do] DOI:10.1002/jcph.210


  9 / 276386 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PubMed Central Texto completo
Texto completo
[PMID]:24571372
[Au] Autor:Schnitzer ME; Moodie EE; van der Laan MJ; Platt RW; Klein MB
[Ad] Dirección:Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
[Ti] Título:Modeling the impact of hepatitis C viral clearance on end-stage liver disease in an HIV co-infected cohort with targeted maximum likelihood estimation.
[So] Fuente:Biometrics;70(1):144-52, 2014 Mar.
[Is] ISSN:1541-0420
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Despite modern effective HIV treatment, hepatitis C virus (HCV) co-infection is associated with a high risk of progression to end-stage liver disease (ESLD) which has emerged as the primary cause of death in this population. Clinical interest lies in determining the impact of clearance of HCV on risk for ESLD. In this case study, we examine whether HCV clearance affects risk of ESLD using data from the multicenter Canadian Co-infection Cohort Study. Complications in this survival analysis arise from the time-dependent nature of the data, the presence of baseline confounders, loss to follow-up, and confounders that change over time, all of which can obscure the causal effect of interest. Additional challenges included non-censoring variable missingness and event sparsity. In order to efficiently estimate the ESLD-free survival probabilities under a specific history of HCV clearance, we demonstrate the double-robust and semiparametric efficient method of Targeted Maximum Likelihood Estimation (TMLE). Marginal structural models (MSM) can be used to model the effect of viral clearance (expressed as a hazard ratio) on ESLD-free survival and we demonstrate a way to estimate the parameters of a logistic model for the hazard function with TMLE. We show the theoretical derivation of the efficient influence curves for the parameters of two different MSMs and how they can be used to produce variance approximations for parameter estimates. Finally, the data analysis evaluating the impact of HCV on ESLD was undertaken using multiple imputations to account for the non-monotone missing data.
[Mh] Términos MeSH primario: Infecciones por VIH/complicaciones
VIH/inmunología
Hepacivirus/inmunología
Hepatitis C Crónica/complicaciones
Modelos Logísticos
Estudios Longitudinales/métodos
Modelos Inmunológicos
[Mh] Términos MeSH secundario: Canadá
Estudios de Cohortes
Infecciones por VIH/inmunología
Infecciones por VIH/virología
Hepatitis C Crónica/inmunología
Hepatitis C Crónica/virología
Humanos
Funciones de Verosimilitud
Masculino
Análisis de Supervivencia
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mes de ingreso:1411
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:140311
[St] Status:MEDLINE
[do] DOI:10.1111/biom.12105


  10 / 276386 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:24400873
[Au] Autor:Hudgens MG; Li C; Fine JP
[Ad] Dirección:Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7420, U.S.A.
[Ti] Título:Parametric likelihood inference for interval censored competing risks data.
[So] Fuente:Biometrics;70(1):1-9, 2014 Mar.
[Is] ISSN:1541-0420
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Parametric estimation of the cumulative incidence function (CIF) is considered for competing risks data subject to interval censoring. Existing parametric models of the CIF for right censored competing risks data are adapted to the general case of interval censoring. Maximum likelihood estimators for the CIF are considered under the assumed models, extending earlier work on nonparametric estimation. A simple naive likelihood estimator is also considered that utilizes only part of the observed data. The naive estimator enables separate estimation of models for each cause, unlike full maximum likelihood in which all models are fit simultaneously. The naive likelihood is shown to be valid under mixed case interval censoring, but not under an independent inspection process model, in contrast with full maximum likelihood which is valid under both interval censoring models. In simulations, the naive estimator is shown to perform well and yield comparable efficiency to the full likelihood estimator in some settings. The methods are applied to data from a large, recent randomized clinical trial for the prevention of mother-to-child transmission of HIV.
[Mh] Términos MeSH primario: Funciones de Verosimilitud
Modelos Estadísticos
[Mh] Términos MeSH secundario: Lactancia Materna/efectos adversos
Simulación por Computador
Femenino
VIH/inmunología
Infecciones por VIH/inmunología
Infecciones por VIH/transmisión
Humanos
Incidencia
Lactante
Recién Nacido
Transmisión Vertical de Enfermedad Infecciosa
Malaui
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Em] Mes de ingreso:1411
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:140311
[St] Status:MEDLINE
[do] DOI:10.1111/biom.12109



página 1 de 27639 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud